A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 06 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Jul 2018.
- 06 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2018.
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.